RxDoctor Payments Data

Sameea Husain, DO

Neurology · Boca Raton, FLNPI 1518160852

Payments from drug & device makers

$47,089in general payments, 2019–2025

Across 298 payments — averaging $158.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$22K
  • Amneal Pharmaceuticals LLC$19K
  • Acorda Therapeutics, Inc$2K
  • Pfizer$618
  • Acadia Pharmaceuticals Inc$351
  • Medtronic$308
  • plus $3K from 30 others

What the payments were for

  • Consulting fees$2,3107%
  • Speaking & faculty fees$23,42771%
  • Travel & lodging$8573%
  • Food & beverage$5,50917%
  • Education$7862%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,089 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$885,955
Medicare patients
537
Services billed
70,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NeuproRotigotine140$272,119
RytaryCarbidopa/Levodopa191$244,387
NuplazidPimavanserin Tartrate32$202,192
AustedoDeutetrabenazine11$59,239
GocovriAmantadine Hcl14$36,604
Entacapone52$12,197
Carbidopa-LevodopaCarbidopa/Levodopa232$11,355
Rasagiline Mesylate72$9,375
Carbidopa-Levodopa ErCarbidopa/Levodopa64$6,625
Primidone77$6,028
Ropinirole Hcl137$5,559
Ropinirole ErRopinirole Hcl32$4,972
AmantadineAmantadine Hcl34$4,349
Topiramate68$3,230
Duloxetine Hcl36$2,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Neupro$295$272,119140 claims
Amneal Pharmaceuticals LLCRytary$19,174$244,387191 claims
Acadia Pharmaceuticals IncNuplazid$351$202,19232 claims
Teva Pharmaceuticals USA, Inc.Austedo$166$59,23911 claims
MDD US Operations, LLCGocovri$289$36,60414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →